| scholarly article | Q13442814 |
| P50 | author | Frederick S Buckner | Q80953280 |
| P2093 | author name string | Nazlee Navabi | |
| P2860 | cites work | New, improved treatments for Chagas disease: from the R&D pipeline to the patients | Q21092295 |
| Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer | Q27658022 | ||
| Nonpeptidic Tetrafluorophenoxymethyl Ketone Cruzain Inhibitors as Promising New Leads for Chagas Disease Chemotherapy | Q27659045 | ||
| Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase | Q27661441 | ||
| In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. | Q43076668 | ||
| In vitro and in vivo experimental models for drug screening and development for Chagas disease | Q43080976 | ||
| Antitrypanosomal and antileishmanial activities of novel N-alkyl-(1-phenylsubstituted-beta-carboline)-3-carboxamides | Q43103796 | ||
| The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles | Q43105784 | ||
| Antitrypanosomal activity of a diterpene and lignans isolated from Aristolochia cymbifera. | Q43124082 | ||
| Trypanocidal activity and acute toxicity assessment of triterpene acids | Q43169544 | ||
| (-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease. | Q43182333 | ||
| New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies | Q43245430 | ||
| The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease | Q43276755 | ||
| Ergosterol biosynthesis and drug development for Chagas disease | Q43276756 | ||
| Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro | Q43610677 | ||
| Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro | Q43715568 | ||
| In vitro effect of a new cinnamic acid derivative against the epimastigote form of Trypanosoma cruzi. | Q45973486 | ||
| 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies. | Q46009231 | ||
| New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships | Q46148069 | ||
| Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. | Q46526596 | ||
| Neolignans from plants in northeastern Brazil (Lauraceae) with activity against Trypanosoma cruzi | Q58844151 | ||
| Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi | Q70627364 | ||
| The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction | Q84012103 | ||
| Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening | Q28474784 | ||
| Actions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on Trypanosoma cruzi | Q28474880 | ||
| Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières | Q28475694 | ||
| Chagas disease | Q29615136 | ||
| Two approaches to discovering and developing new drugs for Chagas disease. | Q33503274 | ||
| Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus | Q33749707 | ||
| Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity | Q33870401 | ||
| Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease | Q33870409 | ||
| A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection | Q33876638 | ||
| Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment | Q33962768 | ||
| Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts | Q33978515 | ||
| In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease | Q34045200 | ||
| Evaluation and treatment of chagas disease in the United States: a systematic review | Q34713358 | ||
| Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase | Q35129381 | ||
| Current treatment approaches to leishmaniasis | Q35539735 | ||
| Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis | Q35644519 | ||
| A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes | Q36516224 | ||
| Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. | Q36670149 | ||
| African trypanosomiasis | Q36709701 | ||
| Treatment of leishmaniasis with miltefosine: 2008 status | Q37249719 | ||
| Rational modification of a candidate cancer drug for use against Chagas disease | Q37274008 | ||
| Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. | Q37390451 | ||
| Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors | Q37392826 | ||
| Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. | Q37408442 | ||
| Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches | Q37629919 | ||
| Diamidine activity against trypanosomes: the state of the art. | Q37659077 | ||
| The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei | Q38956561 | ||
| SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents | Q39023280 | ||
| Naftifine-analogues as anti-Trypanosoma cruzi agents | Q39738205 | ||
| Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies | Q39823446 | ||
| Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action | Q39861737 | ||
| Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi | Q39945921 | ||
| Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors | Q39998125 | ||
| In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi | Q40217643 | ||
| Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. | Q42111347 | ||
| Chagas disease: pushing through the pipeline | Q43008355 | ||
| A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease | Q43069337 | ||
| Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones. | Q43075029 | ||
| P433 | issue | 6 | |
| P921 | main subject | Chagas disease | Q649558 |
| P304 | page(s) | 609-616 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Current Opinion in Infectious Diseases | Q15724406 |
| P1476 | title | Advances in Chagas disease drug development: 2009-2010 | |
| P478 | volume | 23 |
| Q37286061 | Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects |
| Q36565590 | Advances in imaging of animal models of Chagas disease |
| Q36276857 | Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi |
| Q38017721 | Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence |
| Q28543069 | Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line |
| Q27677423 | Biological and Structural Characterization of Trypanosoma cruzi Phosphodiesterase C and Implications for Design of Parasite Selective Inhibitors |
| Q92711796 | Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains |
| Q38253281 | Chagas disease drug discovery: toward a new era. |
| Q39372756 | Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment |
| Q21144502 | Chagas disease: "the new HIV/AIDS of the Americas" |
| Q37879205 | Current status of Chagas disease chemotherapy. |
| Q37390697 | Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice. |
| Q28481694 | Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 |
| Q36086468 | Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies |
| Q35367533 | Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones |
| Q38611251 | Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benzonidazole in Trypanosoma cruzi |
| Q36578029 | Host metabolism regulates intracellular growth of Trypanosoma cruzi. |
| Q39075912 | Identification of novel benzimidazole derivatives as anti-Trypanosoma cruzi agents: solid-phase synthesis, structure-activity relationships and molecular docking studies |
| Q40088256 | Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Trypanosoma cruzi Infection in Mice. |
| Q36656087 | Natural products as a source for treating neglected parasitic diseases |
| Q24597322 | Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease |
| Q26471149 | Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy |
| Q28547166 | Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method |
| Q38203330 | Potential new clinical therapies for Chagas disease |
| Q33632160 | Proteomic analysis of Trypanosoma cruzi response to ionizing radiation stress |
| Q36526649 | Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study |
| Q38178171 | Synthesis of D-galactofuranose-containing molecules: design of galactofuranosyl acceptors |
| Q28476751 | The Trypanosoma cruzi protease cruzain mediates immune evasion |
| Q54246394 | The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures. |
| Q26796451 | Translational challenges of animal models in Chagas disease drug development: a review |
| Q57045450 | Treatment of toxoplasmosis and neosporosis in farm ruminants: state of knowledge and future trends |
| Q28546644 | Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease |
Search more.